Initiator Pharma A/S Total Assets
Initiator Pharma A/S total assets. Based on the latest financial reports, Initiator Pharma A/S (INIT) holds total assets worth Skr36.84 Million SEK (≈ $3.96 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see INIT company net worth for the company's overall valuation and market capitalisation.
Total Assets of Initiator Pharma A/S (2016–2024)
Total assets of Initiator Pharma A/S from 2016 to 2024. This chart illustrates how Initiator Pharma A/S's total assets have evolved over time, based on quarterly financial data. See Initiator Pharma A/S stock price for real-time trading data and today's change.
Initiator Pharma A/S - Asset Composition Analysis
Initiator Pharma A/S Total Assets Breakdown (December 2024)
Initiator Pharma A/S total assets breakdown as of December 2024. Initiator Pharma A/S's total assets of Skr36.84 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 87.4% |
| Accounts Receivable | Skr0.00 | 0.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Initiator Pharma A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Initiator Pharma A/S short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Initiator Pharma A/S's current assets represent 99.9% of total assets in 2024, an increase from 70.7% in 2016.
- Cash Position: Cash and equivalents constituted 87.4% of total assets in 2024, up from 29.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 17.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Initiator Pharma A/S Competitors by Total Assets
Key competitors of Initiator Pharma A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Initiator Pharma A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.53 | 11.79 | 13.06 |
| Quick Ratio | 16.53 | 11.79 | 13.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr34.59 Million | Skr15.73 Million | Skr14.40 Million |
Initiator Pharma A/S - Advanced Valuation Insights
This section examines the relationship between Initiator Pharma A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.44 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -48.7% |
| Total Assets | Skr15.29 Million |
| Market Capitalization | $13.33 Million USD |
Valuation Analysis
Near Book Valuation: The market values Initiator Pharma A/S's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Initiator Pharma A/S's assets decreased by 48.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Initiator Pharma A/S (2016–2024)
The table below shows the annual total assets of Initiator Pharma A/S from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr15.29 Million ≈ $1.65 Million |
-48.66% |
| 2023-12-31 | Skr29.79 Million ≈ $3.21 Million |
-38.39% |
| 2022-12-31 | Skr48.34 Million ≈ $5.20 Million |
-9.97% |
| 2021-12-31 | Skr53.70 Million ≈ $5.78 Million |
+244.17% |
| 2020-12-31 | Skr15.60 Million ≈ $1.68 Million |
+36.41% |
| 2019-12-31 | Skr11.44 Million ≈ $1.23 Million |
-33.99% |
| 2018-12-31 | Skr17.33 Million ≈ $1.86 Million |
+86.36% |
| 2017-12-31 | Skr9.30 Million ≈ $1.00 Million |
+1551.51% |
| 2016-12-31 | Skr563.00K ≈ $60.59K |
-- |
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more